US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

Essential in the formation of leukocytes, lymphocytes, and neutrophils ... It protects cells from oxidative damage caused by free radicals and oxidative stress. It regulates cell apoptosis or cell ...

Osteoarthritis (OA) is the most common arthritis worldwide, causing pain, disability, and loss of function due to chronic joint ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...